Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Newer antidiabetic drugs (SPPARMs, GLP-1 RA and SGLT2i) alone or in combination and acting alone or on the background of potent statin therapy which is recommended in T2DM, might contribute substantially to NAFLD/NASH amelioration, possibly reducing not only liver specific but also cardiovascular morbidity.
|
30961499 |
2020 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to explore the therapeutic effects of the glucagon‑like peptide‑1 (GLP‑1) receptor agonist liraglutide (LRG) on NASH and the underlying mechanisms.
|
31180545 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we exemplify the utility of this procedure by leveraging the pre-study biopsy to assess the impact of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide on NASH endpoints in mice.
|
31058888 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we provide an overview of the role of GLP-1 and GLP-2 in lipid homeostasis and metabolic disease including NAFLD and NASH.
|
30578967 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, there is an increasing interest regarding the effects of newer anti-diabetic drugs, such as dipeptidyl peptidase 4 inhibitors (DPP-4i), sodium glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on NAFLD/NASH.
|
31672448 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This may have significant clinical implications to the potential mechanism of action of GLP-1 receptor agonists in patients with NASH.
|
31082799 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor (GLP-1R) agonists have significant therapeutic effects on non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) in animal models.
|
30510243 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
From this analysis, we can conclude that the multi-target beneficial action of the GLP-1 analogues could explain the positive effects observed in animal and human models on progression of NAFLD to NASH.
|
30359962 |
2018 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Miglitol treatment suppressed HFHSD-induced NASH development with the suppression of hepatic Toll-like receptor 4 expression, increased glucagon-like peptide 1 (GLP-1) concentration, and reduced lipopolysaccharide concentration in portal plasma.
|
28349245 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 analogues and SGLT-2 inhibitors are currently approved for use in diabetes, have shown early efficacy in NASH and also have beneficial cardiovascular effects.
|
28677333 |
2017 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets.
|
29107284 |
2017 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GLP-1r is expressed in human hepatocytes, although reduced in patients with NASH.
|
21745271 |
2011 |